Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Gene therapy targeting striatal dysfunction for Parkinson’s disease

Award Number: R01NS126924
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2022
PERIOD OF PERFORMANCE END DATE: 01/31/2027

Group Awards By:

View Award Description

Gene therapy targeting striatal dysfunction for Parkinson’s disease - Project Summary Parkinson’s disease (PD) is characterized by motor abnormalities primarily caused by loss of midbrain dopamine (DA) cells, which significantly modulate striatal neurons. DA depletion is thus associated with altered function of striatal projection neurons (SPNs). SPN dysregulation is evidenced by significant morphological and physiological changes, as shown in numerous ex-vivo and in-vivo studies. Furthermore, our studies in primate models and patients have revealed pathological hyperactivity of SPNs. A key contributor to this hyperactivity is the excitatory glutamate signaling. This has been recently demonstrated with selective striatal blockade of NMDARs. The block reduces hyperactivity and controls the altered neuronal responses to DA replacement. Furthermore, it has significant effects on parkinsonian motor symptoms. Therefore, data support that reducing NMDAR signaling on SPNs may have therapeutic effects in PD. Given the largely conserved structure of NMDARs across brain regions, pharmacotherapies are generally limited by widespread drug actions. We recently tested gene therapies targeting NMDAR subunit expression in the striatum. Our preliminary data generated with exploratory tests in rodents showed that, indeed, gene knockdown (KD) of GluN2 subunits may offer a novel therapeutic strategy to improve motor symptoms of PD. Thus, data support advanced preclinical studies of GluN2 gene KD in non-human primates (NHP) for extensive evaluation of this gene therapy in the gold-standard model of PD. In this project we plan to demonstrate “efficacy” of GluN2 gene KD for various motor and cognitive symptoms of PD. The studies will use primate MPTP models and shRNA viral vector injections in the striatum to suppress gene expression of GluN2 in SPNs. A battery of motor and cognitive tests will be used over a prolonged term post-virus administration to determine stable, chronic effects. Taking advantage of PD modeling in NHPs, different disease stages will also be evaluated. We also include additional outcome measures to evaluate “safety” of targeting the proper assembly of NMDAR in the striatum. Finally, we will validate this gene therapy with electrophysiology data demonstrating specific effects on altered SPN activity, and applying optogenetics. for cell resolution in NHP recordings. Overall, the research strategy in this proposal is based on optimal animal models, viral vectors of proven efficiency, extensive testing of motor, cognitive, and other behaviors, and precision tools for electrophysiology. We expect that results of these studies demonstrate efficacy and safety with translational data to support further development of striatal GluN2 gene therapy for PD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $507,831 )
2026	2026	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	1/16/2026	NON-COMPETING CONTINUATION	$457,048
2026	2026	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	5	3/5/2026	NON-COMPETING CONTINUATION	$50,783
														Subtotal = $507,831

Issue Date FY: 2025 ( Subtotal = $496,466 )
2025	2025	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	1/15/2025	NON-COMPETING CONTINUATION	$496,466
														Subtotal = $496,466

Issue Date FY: 2024 ( Subtotal = $535,690 )
2024	2024	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	2/12/2024	NON-COMPETING CONTINUATION	$497,033
2024	2024	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	3	4/9/2024	NON-COMPETING CONTINUATION	$38,657
														Subtotal = $535,690

Issue Date FY: 2023 ( Subtotal = $561,514 )
2023	2023	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	4/6/2023	NON-COMPETING CONTINUATION	$561,514
														Subtotal = $561,514

Issue Date FY: 2022 ( Subtotal = $559,773 )
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	1	9/9/2022	NEW	$77,003
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	1/28/2022	NEW	$482,770
														Subtotal = $559,773

Grand Total All Awards = $2,661,274

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Gene therapy targeting striatal dysfunction for Parkinson’s disease

Award Number: R01NS126924

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2022

PERIOD OF PERFORMANCE END DATE: 01/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer